Category: free-access

KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Summary Merck (NYSE: MRK) has announced positive findings from the Phase 3 KEYNOTE-689 trial, which evaluated the use of KEYTRUDA® (pembrolizumab) as a perioperative treatment for patients with locally advanced…